Resources:

Find resources by:

Sort by:

Date Resource A-Z Random

Resources from the last:

Box size:

Filer text box:

Topic familiarity:

Grid Layout:

Collections that use this topic:

Collection topics:

Adrenal Bone Cardiovascular Diabetes Endocrine-Disrupting Chemicals Endocrine-Related Cancer Metabolism Neuroendocrinology Obesity Reproduction Steroid and Steroidogenesis Thyroid

BiosciAlliance - Conditions Prostate

Obesity Diabetes Acromegaly Diabetes Insipidus Endometriosis Prostate Rare Disease Eye Disease Growth

Prostate Cancer Charity

Congratulations to the awardees of our third round of 2024 grants

Congratulations to the Winners of the SfE Journal Awards!

Prostate cancer drugs linked to increased risk of metabolic and cardiovascular issues

New test to help identify prostate cancer in black males hopes to reduce deaths

New insights on the human androgen receptor

Prostate cancer survival improved by combined radio- and hormone therapy

Prostate cancer treatment rejected in England and Wales

New androgen research may improve treatments for cancer

New oral hormone drug for prostate cancer

Autumn issue of The Endocrinologist is online now!

Autumn issue of The Endocrinologist is online now!

Exercise may help improve immune system in prostate cancer

Exercise may help improve immune system in prostate cancer

Prostate cancer death rate declining

Prostate cancer death rate declining

Hormone therapy may help treat prostate cancer

Hormone therapy may help treat prostate cancer

Exercise may help reduce side effects of prostate hormone therapy

Exercise may help reduce side effects of prostate hormone therapy

Breast and ovarian cancer drugs shown to effectively treat prostate cancer

Breast and ovarian cancer drugs shown to effectively treat prostate cancer

Targeted radiotherapy found to significantly cut treatment time for prostate cancer

Targeted radiotherapy found to significantly cut treatment time for prostate cancer

Link between hormone therapy and dementia risk proposed

Link between hormone therapy and dementia risk proposed

Full-time post-doctoral research position available at Baylor College of Medicine

Radiation and hormone therapy may extend survival in prostate cancer patients

Adverse effects of hormone therapy in prostate cancers

Urological problems linked with depression and sleep disorders

Bariatric surgery may reduce hormone-related cancer risk

ICSI treatment linked to increased prostate cancer risk

LED lighting increases hormone-related cancer risk

How to reduce hormone therapy side effects in prostate cancer treatment

Potential new target for reducing osteoporosis risk in men

Androgen deprivation therapy linked to cardiovascular risk

Tall men have greater risk of developing prostate cancer

Jasmine-compound and standard-therapy combination show promise as BPH treatment

Hormone blockers can prolong life if prostate cancer recurs

Prostate cancer hormone therapy tied to higher dementia risk

Hormone therapy for prostate cancer may raise dementia risk

Gene that drives aggressive prostate cancer identified

Sponsored Symposium: Translating molecular insights into clinical practice in breast and prostate cancer

Hormone therapy for prostate cancer may pose a risk for black men

Prostate cancer aggression linked to waist size

Radiotherapy halves deaths from prostate cancer 15 years after diagnosis

Low Vitamin D may mean aggressive prostate cancer

Clinical implications of androgen receptor in prostate cancer stem cells

Lower 25-hydroxyvitamin D levels associated with adverse pathology in radical prostatectomy

Postdoctoral research fellows and staff scientist - Kantoff Lab, New York, United States

Prostate cancer treatment tied to Alzheimer’s risk

Long-term 'T' Does Not Up Risk for High-grade Prostate Cancer

Highlights from the ESE Journals

Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications

Postdoc positions in Stem Cell, Developmental and Cancer Biology at UCSC, Santa Cruz, USA

Two Postdoctoral Research Associate Positions, Imperial College, UK

Cell cycle regulation of androgen receptor

HES5 silenced early in prostate tumourigenesis

TMEFF2 and CRH signalling

GPR30-targeted therapy with G-1 in CRPC

Faculty positions in cancer biology – Oregon, USA

Sex with more than 20 women reduces risk of prostate cancer, according to study

Prostate drugs treble heart death risk for some patients

Disseminated prostate cancer cells in bone

Going bald? You may face a higher risk of aggressive prostate cancer

Postdoctoral research fellow – Edinburgh, UK

No evidence, yet ADT often used in localized prostate cancer (Medscape, 16 July 2014)

Prostate cancer biomarkers identified in seminal fluid (EurekAlert, 6 June 2014)

RANK and c-Met in prostate cancer

Six months hormone therapy in addition to radiotherapy improves prostate cancer survival (Medical Xpress, 7 April 2014)

Primary androgen deprivation therapy ineffective for most men with early prostate cancer (Medical Xpress, 17 March 2014)

Bone turnover markers predict prostate cancer outcomes (EurekAlert, 7 March 2014)

Prostate cancer signal reawakens 'sleeper agent' cells in bones (Medical Xpress, 29 January 2014)

Radiotherapy plus hormone therapy halved prostate cancer mortality (Healio, 28 January 2014)

Melatonin may lower prostate cancer risk (EurekAlert, 19 January 2014)

BPA linked to prostate cancer? (MedPage Today, 16 January 2014)

Zebrafish as an innovative model for neuroendocrine tumours (Endocrine-Related Cancer, 29 November 2013)

GNMT regulation in prostate cancer

IRF and IL6 in prostate cancer

Intraprostatic androgen maintenance

Drug safely cuts prostate cancer risk, study finds (Associated Press, 14 August 2013)

Postdoctoral Fellowship: new treatments for prostate cancer by targeting steroid receptor signaling - Baylor College of Medicine, Texas, USA

Postdoctoral Fellowship: new treatments for prostate cancer by targeting steroid receptor signaling - Baylor College of Medicine, Texas, USA

Dysregulation of the IGF-1 receptor and possibile new therapeutic approaches (Catanzaro, Italy)

Research Officer - Prostate Cancer UK

Record gene haul points to better cancer screening (Reuters, 27 March 2013)

A novel insulin-regulated ghrelin transcript

1 disease, 2 mechanisms (EurekAlert, 11 February 2013)

Increasing effectiveness of androgen deprivation

Prostate Cancer UK Sponsored Fellowships

PhD studentships, University of Birmingham

Metabolic factors may increase men's risk of dying from prostate cancer (AlphaGalileo, 22 October 2012)

Obesity promotes prostate cancer by altering gene regulation (AlphaGalileo, 25 September 2012)

Obesity, diabetes mellitus, and cancer

Reducing the side effects of treatment for prostate cancer (AlphaGalileo, 28 August 2012)

Postdoctoral positions, University Hospital Zurich, Switzerland

Suppressor role of AR in prostate basal cells

ESE Official Journals

A study confirms the correlation between premature alopecia and prostate conditions (AlphaGalileo, 15 March 2012)

Sorafenib and prostate cancer therapy resistance

Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases (Reuters, 10 February 2012)

Communication Between Peri-Prostatic Adipocytes and Epithelial Cells Drives Prostate Cancer Aggressivity in Obese Men

Novel treatment approaches for breast and/or prostate cancer

A novel MiR-346-directed DNA damage mechanism is regulated by its interaction with long non-coding RNA, NORAD, in prostate cancer

Regulation of androgen receptor function in prostate cancer

How do I manage testosterone replacement after prostate cancer therapy?

Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotesto...

Hypogonadism in a man with cancer of the prostate

Extracellular vesicles from the peri-prostatic adipose tissue from obese, but not lean, men promotes prostate cancer aggressivity

Evaluating the complex interplay between androgen deprivation therapy, sleep disturbance and nocturia in prostate cancer. A systemic review of prospective studies, and consideration of the emerging role of transdermal oestrogen

Treating castration-resistant prostate cancer with supraphysiological testosterone

MiR-16-5p and -424-5p: master regulators of cell cycle progression in prostate cancer

Mechanisms of skeletal metastasis (could be induced by breast cancer or prostate cancer or both)

Neuronostatin and GPR107 system: a novel therapeutic circuit in Prostate Cancer.

Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic ...

Prolactin regulation of prostate stem cells : potential implications in prostate cancer

Prostate cancer and surrounding fat - a dangerous duo

The truncated somatostatin receptor sst5TMD4 is overexpressed in prostate cancer, where it increases...

Oestrogen receptor α (ERα) promotes prostate cancer progression through dual actions in both epithel...

Androgen metabolism and synthesis in prostate cancer

Androgen action and gene expression in prostate cancer

Regulation of stroid receptor expression and proliferation in prostate cancer by genistein and other...

Activation of androgen membrane binding sites induce potent regression of prostate cancer cells in v...

Lecture: Defining androgen receptor regulatory grammar in prostate cancer

Breast and prostate cancer - more similar than different

Genetic susceptibility and risk stratification for prostate cancer screening and prevention

Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selec...

Persistent AR activity in enzalutamide resistant prostate cancer?

Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent c...

New combination therapies for castration-resistant prostate cancer

Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer

Transcriptomic and functional landscape of circular RNA in prostate and breast cancer

Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer

Cell plasticity in treatment resistant prostate cancer

Androgen interference with prostate cancer response to Cabazitaxel

Immunotherapy in prostate cancer: challenges and progress

Convergence of regenerative medicine principles to develop new breast and prostate cancer mice model...

DACH1 gene deletion extends portraits of human prostate cancer

The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?

Molecular stromal signatures in the supportive bone microenvironment of breast and prostate cancer

ERRa regulates prostate cancer cell colonization in bone

Cripto/GRP78 Signalling in Dissemination and Metastasis of Human Osteotropic Prostate Cancer

Endothelin-1, a Gene Regulated by TMPRSS2:ERG Fusion Proteins in Prostate Cancer Bone Metastases

BMP7 Inhibits Prostate Cancer Metastases by Depletion of Metastasis-Initiating Cancer Stem Cells

Long non-coding RNAs in Prostate Cancer Progression

FZD5 Mediates the Anti-Proliferative, but not the Pro-Apoptotic Effects of WNT5A on Prostate Cancer ...

miR-25 and miR-21 Regulate Prostate Cancer Invasiveness by Attenuation of Notch-TGF-β Crosstalk and ...

Salinomycin Treatment Inhibits Prostate Cancer Growth In Vitro, In Vivo and in Near-Patient Ex Vivo ...

WNT5A has anti-prostate cancer effects and protects against bone metastases

Resource not read: Query You and Your Hormones

Soluble CD105 is prognostic of prostate cancer recurrence

PEG10 is associated with treatment-induced neuroendocrine prostate cancer

Hormones and hormomirs: MicroRNAs in prostate cancer therapy

ERC Summer 2017 paper

How does obesity affect PSA?

Images in endocrinology

Twists and challenges in resistance to hormonal therapies for cancer

25 YEARS OF OESTROGEN RECEPTOR-β

SEX DIFFERENCES IN THE CARDIOVASCULAR EFFECT OF GNRH ANALOGUES

MALE HYPOGONADISM AND TESTOSTERONE REPLACEMENT

ACT001 REVERSES DRUG RESISTANCE OF PROLACTINOMAS

Endocrine cancer progression and metastases

Male hypogonadism and ageing: rejuvenating the guidance

Talking face to face: the value of the Society’s Themed Scientific Meeting Grant

2020 Awardees: Leadership & Development Awards Programme

Publishing round-up

A word from the Editor

Exercise intensity, inflammation and cancer treatment

Working at the intersection: cross-disciplinary endocrinology

Recognising and rewarding excellence

Endocrinologists and the consequences of cancer treatment

Endocrine-Related Cancer: Present challenges and new opportunities

Early Career Prize Lecturers 2018, Clinical: Neurokinin 3 receptor antagonists – the magic bullet for hot flushes?

Endocrinologist 137 Web

Endocrinologist 137 Web.pdf (1)

Milestones In Endocrinology

Endocrinologist 131 Web Updated

ScreenSummerEndoComplete.pdf

The Endocrinologist 116 Web FINAL v2.pdf

Endocrinologist 143 Web

Endocrinologist 124 Web

Endocrinologist 122 FINAL Web.pdf

Endocrinologist 135 Web

The Endocrinologist 117 Web.pdf

The Endocrinologist 115 Web FINAL.pdf

Endocrinologist 129 Web

The Endocrinologist 132.pdf

The Endocrinologist spring14 web version FINAL.pdf

The Endocrinologist Autumn 14 -website.pdf

Endocrinologist 142 Web (1)

Endocrinologist 142 Web

Endocrinologist 141 Web

The Endocrinologist 114 Web.pdf

Endocrinologist 151 Final

Endocrinologist 121 Web final.pdf

Endocrinologist 123 Web

Endocrinologist 133 Web

Endocrinologist 140 Web

Isolation, propagation and characterisation of primary prostate cancer epithelial cell lines from prostate specimens

Resistant hypocalcaemia in a patient with prostatic adenocarcinoma with extensive osteoblastic metastasis

Clinical correlates of enlarged prostate size in subjects with sexual dysfunction

Biomarkers of prostate cancer transgenerational transmission risk in the progeny of obese fathers subjected to dietary correction

Causes and consequences of metabolic changes in prostate tumours

The impact of mycophenolate mofetil on androgen receptor activity in prostate cancer cells 22Rv1

Potential prostate cancer drug therapy targets bioactivation of androstanediol to dihydrotestosterone

Androgen receptor: master contortionist in prostate cancer

Prostate cancer microRNAs in extracellular vesicles stimulate osteoclastogenesis

Vitamin D from genetics to the clinical in prostate cancer

Modulating glucocorticoid receptor function in breast and prostate cancer

Mediators of stress resistance in prostate cancer cells

Severe cushings syndrome associated with metastatic prostate adenocarcinoma

ELL2 and EAF2 co-regulation of AKT in prostate cancer cells

After up to 13 years observation, testosterone undecanoat 1000 mg at 3 months did not increased Prostatic Specific Antigen level. Relation with prostatic volume (January 2021)

Androgen receptor variants and microenvironment in prostate cancer

The effect of undecanoat testosterone depot on the prostate volume

The effect of melatonin on pC3 prostate cancer cells <em>in vitro</em>

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

A review of cimetidine (tagamet) effects as a reoproductive toxicant in male rats prostate and seminal vesicle

After up to 11 years observation, testosterone undecanoat 1000 mg at 3 months did not increased Prostatic Specific Antigen level (January 2019)

Chromatin relaxation is a feature of advanced prostate cancer

Unveiling the therapeutic role of somatostatin and cortistatin in prostate cancer

IGF-2 Mediated Hypoglycaemia, secondary to Adenocarcinoma of the Prostate

After 9 years observation, testosterone undecanoat 1000 mg at 3 months did not increased Prostatic Specific Antigen level (December 2016)

Prolactin and prostate: an observational case-control study in men with prolactinoma under cabergoline treatment

MicroRNA drivers of resistance to androgen deprivation therapy in prostate cancer

Testosterone undecanoate 1000 mg at 3 months did not increased prostatic specific antigen level: January 2015

Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation

Cushings Syndrome secondary to ACTH-producing prostate adenocarcinoma: A case report

Testosterone levels are the main determinant of prostate volume in men with chronic spinal cord injury

Identification of AR genomic targets in mesenchymal cell subsets during prostate development

Survey of gene expression during prostate cancer progression using tissue microarrays

Potential therapeutic role of somatostatin and cortistatin in prostate cancer

Glycosylation is a global target for androgen control in prostate cancer cells

Cellular plasticity and neuroendocrine phenotypes in prostate cancer

μ-Crystalline as hormone antagonist in prostate cancer

Metastases-prone localized prostate cancer: a genomic analysis

14.18. Darolutamide in nonmetastatic, castration-resistant prostate cancer

Epigenetic regulation of androgen receptor function in prostate cancer

Cripto/Grp78 drive the metastatic phenotype in human osteotropic prostate cancer

Type 2 diabetes and prostate cancer risk in Korean men with low PSA

Targeting DNA repair-AR crosstalk dysfunction in advanced prostate cancer

WNT5A has anti-prostate cancer effects and protects against bone metastases

When a common symptom leads to a rare diagnosis  prostate metastasis in the pituitary

Androgen receptor binding sites are highly mutated in prostate cancer

Testosterone effect on immature prostate gland growth in dogs associated with suppression of TGF-beta mRNA expression

Androgen pathway regulating microRNAs in prostate cancer progression and therapy

Adiponectin receptor expression in human prostate cancer cell lines

IGF2 producing prostate tumour causing severe hypoglycaemia: case report